Products

 
 

Moventig®

Active Ingredient: 
Naloxegolum ut Naloxegoli oxalas
Condition:
For the treatment of adult patients with opioid-induced constipation (OIC) associated with pain of non-malignant origin

Tostran®

Active Ingredient:
Testosterone
Condition:
Male hypogonadism

Rectogesic®

Active Ingredient:
Glyceryl trinitrate
Condition:
Chronic anal fissure

Gynomunal®

Class IIa Medical Device
Condition:
Vaginal Moisturizing Gel with natural hop extract & Vitamin E


 

About Moventig®

Product information provided on this website is intended for Healthcare Professionals only. If you are a patient seeking further information you should consult your own doctor about your condition and appropriate treatment.

Cederberg only has rights to commercialise Moventig® in Switzerland and Liechtenstein.

Further Information
Swissmedic approved information can be found here.

You are leaving the Cederberg website and Cederberg is not responsible for the content that you will view.

If you are a qualified Healthcare Professional and need further medical information or assistance, you may contact our Medical Information / Drug Safety service.

 

About Tostran®

Product information provided on this website is intended for Healthcare Professionals only. If you are a patient seeking further information you should consult your own doctor about your condition and appropriate treatment.

Cederberg only has rights to commercialise Tostran® in Switzerland and Liechtenstein.

Further Information
Swissmedic approved information can be found here.

You are leaving the Cederberg website and Cederberg is not responsible for the content that you will view.

If you are a qualified Healthcare Professional and need further medical information or assistance, you may contact our Medical Information / Drug Safety service.

 

About Rectogesic®

Product information provided on this website is intended for Healthcare Professionals only. If you are a patient seeking further information you should consult your own doctor about your condition and appropriate treatment.

Cederberg only has rights to commercialise Rectogesic® in Switzerland and Liechtenstein.

Further Information
Swissmedic approved information can be found here.

You are leaving the Cederberg website and Cederberg is not responsible for the content that you will view

If you are a qualified Healthcare Professional and need further medical information or assistance, you may contact our Medical Information / Drug Safety service.

 

Gynomunal®

Vaginal moisturiser with natural hop extract and Vitamin E.

Vaginal dryness is very common - up to 55% of menopausal women have it. (1, 2) It is also common in women immediately after childbirth or during breastfeeding. It can occur in women taking contraceptives, at times of stress or as a result of radiotherapy or chemotherapy. (1, 3, 4)

Gynomunal is a vaginal moisturising gel containing natural hop extract – a source of phytoestrogens - long thought to be beneficial for gynaecological conditions. Gynomunal also contains Vitamin E which has anti-oxidant and anti-inflammatory properties and helps wound healing and tissue regeneration. Gynomunal’s liposomal formulation also contains hyaluronic acid - a naturally occurring substance - that provides a protective film for damaged tissues as well as providing last-lasting hydration.

A clinical study of 100 post-menopausal women who used Gynomunal showed rapid relief of vaginal dryness within one-week and a 58% improvement after one month. The clinical study also showed significant and rapid relief from symptoms of itching, burning and pain as well as for inflammation, swelling and rash. (5)

In the UK you can buy Gynomunal on-line at www.gynomunal.co.uk and over-the-counter at pharmacies. It is available either with or without prescription.

1.Ghumman S. Atrophic Vaginitis: Diagnosis and Treatment. J South Asian Feder Menopause Soc 2013; 1(1):4-12.
2.Johnston SL, Farrell SA. The detection and management of vaginal atrophy. SOGC Clinical Practice Guidelines. No. 145, May 2004.
3.Mac Bride MB, Rhodes DJ, Shuster LT. Vulvovaginal Atrophy. Mayo Clin Proc. January 2010;85(1):87-94 DOI:10.4065/mcp.2009.0413.
4.NHS Direct. Accessed 30 September 2013 https://www.nhs.uk/conditions/vaginal-dryness/
5. Morali G, Polatti F, Metelitsa EN, Mascarucci P, Magnani P, Marrè GB. Open, non-controlled clinical studies to assess the efficacy and safety of a medical device in form of gel topically and intravaginally used in postmenopausal women with genital atrophy. Arzneimittelforschung. 2006;56(3):230-8.

Innovative Healthcare Solutions

Get in touch

Please feel free to get in touch. You can use the on our contact page or you can complete the form below and we will respond to you.

Image use is for illustrative purposes only. The people depicted act as models only.
Privacy Statement / Legal